(Q53145096)

11 May 2018

title

Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer. (English)

1 reference

11 May 2018

0 references

2

1 reference

11 May 2018

Ren-In You

object named as

Ren-In You

4

0 references

author name string

Ming-Shen Dai

1

1 reference

11 May 2018

Man Xu

3

1 reference

11 May 2018

Yu-Feng Hsieh

5

1 reference

11 May 2018

Laure-Hélène Ouisse

6

1 reference

11 May 2018

Kai-Yu Lo

7

1 reference

11 May 2018

Huey-Kang Sytwu

8

1 reference

11 May 2018

Tsu-Yi Chao

9

1 reference

11 May 2018

language of work or name

English

0 references

publication date

14 September 2012

1 reference

11 May 2018

published in

Vaccine

1 reference

11 May 2018

volume

30

1 reference

11 May 2018

issue

48

1 reference

11 May 2018

page(s)

6903-6911

1 reference

11 May 2018

Recombinant E. coli efficiently delivers antigen and maturation signals to human dendritic cells: presentation of MART1 to CD8+ T cells.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Recombinant E. coli LLO/OVA induces murine BMDCs maturation via TLR4 and NOD1 receptor and promotes specific cytotoxic T cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Development of an Escherichia coli expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Recombinant Escherichia coli expressing invasin targets the Peyer's patches: the basis for a bacterial formulation for oral vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

An MVA vaccine overcomes tolerance to human p53 in mice and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

The prime-boost strategy: exciting prospects for improved vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Heterologous prime-boost vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Regulation of immunity by self-reactive T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

A pool of central memory-like CD4 T cells contains effector memory precursors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

DNA vaccination strategies for anti-tumour effective gene therapy protocols.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

DNA vaccines: developing new strategies against cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors im

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

CD25+ regulatory T cells and tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Progress in DNA-based heterologous prime-boost immunization strategies for malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Prime-boost strategies for malaria vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Regulatory T cells in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.001

10.1016/J.VACCINE.2012.09.001

7 January 2021

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018